Dr. Christopher C Dvorak, MD
Claim this profileUniversity of California, San Francisco
Studies Acute Graft-versus-Host Disease
Studies Graft-versus-Host Disease
3 reported clinical trials
4 drugs studied
Affiliated Hospitals
Clinical Trials Christopher C Dvorak, MD is currently running
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
CliniMACS® T-Cell Depletion
for Stem Cell Transplant Patients
Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situations, the optimal approach to minimize the risk of GVHD is to perform ex vivo alpha-beta T-cell depletion of the donor cells. However, the CliniMACS® Device is FDA-approved only for a narrow indication. All other uses of ex vivo processed cells must be done under a feasibility study protocol.
Recruiting1 award N/A
More about Christopher C Dvorak, MD
Clinical Trial Related6 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christopher C Dvorak, MD has experience with
- CliniMACS®
- Busulfan
- Cell Processing For TCRαβ+/CD19+ Depletion
- N/A
Breakdown of trials Christopher C Dvorak, MD has run
Acute Graft-versus-Host Disease
Graft-versus-Host Disease
GVHD
Severe Combined Immunodeficiency
Quality of Life
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Christopher C Dvorak, MD specialize in?
Is Christopher C Dvorak, MD currently recruiting for clinical trials?
Are there any treatments that Christopher C Dvorak, MD has studied deeply?
What is the best way to schedule an appointment with Christopher C Dvorak, MD?
What is the office address of Christopher C Dvorak, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.